Art

J-GLOBAL ID：201702258996560058   Reference number：17A0177604

Effect of Predialysis Recombinant Human Erythropoietin on Early Survival After Hemodialysis Initiation in Patients With Chronic Kidney Disease: Co-JET Study

慢性腎疾患患者での血液透析開始後の初期生存への透析導入前の組換えヒトエリスロポエチンの効果:Co-JET研究

Author (17)： Watanabe Yuzo (Department of Internal Medicine, Kasugai Municipal Hospital, Kasugai, Aichi, Japan) ,  Akizawa Tadao (Department of Nephrology, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan) ,  Saito Akira (Department of Nephrology, Shonan Tobu Sogou Hospital, Chigasaki, Kanagawa, Japan) ,  Gejyo Fumitake (Niigata University Graduate School of Medicine and Dental Sciences, Chuoku, Niigata, Niigata, Japan) ,  Suzuki Masashi (Shinraku-en Hospital, Nishi-ku, Niigata, Niigata, Japan) ,  Nishizawa Yoshiki (Osaka City University Graduate School of Medicine, Abeno, Osaka, Japan) ,  Tomino Yasuhiko (Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo, Japan) ,  Tsubakihara Yoshiharu (Course of Safety Management in Health Care Sciences, Graduate School of Health Care Sciences, Jikei Institute, Yodogawa-ku, Osaka-shi, Japan) ,  Tsubakihara Yoshiharu (Osaka, Japan) ,  Akiba Takashi (Department of Blood Purification, Kidney Center, Tokyo Women’s Medical University, Shinjyuku-ku, Tokyo, Japan) ,  Hirakata Hideki (Department of Nephrology, Fukuoka Red Cross Hospital, Minami-ku, Fukuoka, Fukuoka, Japan) ,  Kawanishi Hideki (Department of Artificial Organs, Tsuchiya General Hospital, Naka-ku, Hiroshima, Hiroshima, Japan) ,  Bessho Masami (Department of Hematology, Saitama Medical School, Moroyama-cho, Iruma-gun, Saitama, Japan) ,  Udagawa Yukio (Pharmacovigilance Department, Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan) ,  Aoki Kotonari (Pharmacovigilance Department, Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan) ,  Uemura Yukari (Biostatistics Division, Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan) ,  Ohashi Yasuo (Department of Integrated Science and Engineering for Sustainable Society, Chuo University, Bunkyo-ku, Tokyo, Japan)
Material： Therapeutic Apheresis and Dialysis  (Ther Apheresis Dial)
Volume： 20  Issue： 6  Page： 598-607  Publication year： Dec. 2016 
JST Material Number： W1443A  ISSN： 1744-9979  Document type： Article
Article type： 原著論文  Country of issue： Australia (AUS)  Language： ENGLISH (EN)

Thesaurus term： *kidney disease ,...
Semi thesaurus term： *Chronic renal disorder ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0177604&from=J-GLOBAL&jstjournalNo=W1443A") }}

Author keywords (4)： Chronic kidney disease ,  Erythropoiesis-stimulating agent ,  Hemodialysis ,  Mortality

JST classification (1)： Clinical application of drugs acting on blood and body fluid  (GW14020X)

Reference (15)：

• Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K, Narita I. Cause-specific excess mortality among dialysis patients: comparison with the general population in Japan. Ther Apher Dial 2013;17:298-304.
• Robinson BM, Zhang J, Morgenstern H et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int 2014;85:158-65.
• Tsubakihara Y, Gejyo F, Nishi S et al. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial 2012;16:529-40.
• Fink JC, Blahut SA, Reddy M, Light PD. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348-55.
• Lu WX, Jones-Burton C, Zhan M, Salzberg DJ, Moore J Jr, Fink JC. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract 2005,101:c79-86.

Terms in the title (8)： 慢性 ,  腎疾患患者 ,  血液透析 ,  初期 ,  生存 ,  透析導入 ,  組換えヒトエリスロポエチン ,  研究